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and distal non.lrosted sagmenls. Plaque area In the distal segment showed 
also no signklcsnt increase. A signillcnnl increase 01 IhQ plflque area rn the 
pmslmnl sagmont wss found at &month fOllOW*UP. 
- 
Prox~mnl soamonl Dlntnl soomant 
pant PTCA lollow.up pmt PTCA lallowup 
~~seel Rtsn(mm2) 20.1 t 6.7 10.7 L G.Apn 0.52 14.2.1 3.0 13.0 i: 3.7PnO.46 
p1q~ln~ron(mm") 7.3. t.3.7 7.0 C 4.U' pmO.010 6.7 -i 3.4 6.2 zk 3.6 PC 0.10 
c~ncluslan: IVUS domanslrated A plaque progresslon only In the proxlmsl 
nan+asled segmen\ but not In the distal non4realQd sogmant suggashng 
lhst alhQronclarollQ prograflalon ,rilght ba pnnly rosultad ham ondolhallsl 
dsmngaa during Imorvanllon such sn bnlloon pflsRng0. 
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Esckgroud: Endothalln blndlng to ETA allmulnlas vnsculnr smoalh muscle 
cell pmllfamtlon nnd, thus. may be plvolnlly lnvolvod In Iho palhogonasm 
of restQnosls. This study was daslgnad lo flasoss tha nblllty al a patant 
nnd soloctlve ETA onlngonlst to mduca noolnllmnl hyporplflsm In a pamlno 
coronary stem In)ury modal. 
Methods and Rosub: Oml drug wfls admlnlstorad twlca dally In capsule 
torn? Qt dnRQR of a.75 mg&g (low), 3.75 mglkg (mid) and 10.6 mglkg (high). 
Fllty-seven plgs had stents doployed In anch ol two rnndomly asslgnod major 
oplcardlnl coranary mtarlas. Thlnaon plgslgmup survlvod wilhoul compllca 
tlon until predetannmad sncrllice al 28 days. ET.1 lmmunoraectivily was 
observod wlthln tho noolntima of nil stonlod comnnty sogmonls and concan. 
tratod nt lho silos of strut mtury. Compamd to placebo. injuty was stgnlhcnntly 
grenlar in mtd nnd htgh dose gmups. whtlo naotntimel Ihtcknass (NI) was $19 
nWmlly lass m low nnd high doso ~nimnls. 
___ 
Pi.llV!xl 1 Oh #PSP AhI dose __ ._._. -. - - .- _~___~_~ .-___-_ 
IrliUrY scorn 1 73 , 080 179 IO7:, IO4 1 092’ 
NI (mm) 0 45 t 0 24 0 38 t 0 22’ 0.40 * 0.25 -- 
(‘P 005) 
Hrgh dose 
1 !lJ I 0 73’ 
0 37 t 0.37’ 
Coflcfusion: Ornl solaclivo ETA recoplor rtnlngonism stgnilicanlly reduces 
noomtimttl hyporplnstn in Iho first 26 days following coronary stenling in Ihis 
porcine modal and. thus. has clinical potontlnl for limiting coronary rastenosis 
tollowing porcutnnaous revasculortration. 
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We have al~ady reported the efficacy of trantlast on preventlon of restenosts 
tOllOwIng perCUtaneOuS translumional coronery angtoplasty (PEA) in the 
multicenter study (TREAT-P). In the sludy, we also analized the dtfference 
of the responses on de nova lesions or restenosts lesions following PTCA. 
Trantlast was gtven 600 mg Per day over 6 weeks attor successlul PTCA and 
folloWuP angiograms were performed at three monlhs. Data were analized 
by CCA, snt restenosis was defined as a lass of more than SO% at inittal 
gain. 
lesion 
lranllasl (It) 
plncebo,“, 
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JACC RhnliIv IWX 
Trsnllast reduced the restenosls rate both for de novo lesions and restenosls 
loslons. However, the reducllon of reslonosls rnto we8 54% In de novo le. 
slons and 66% In roslenotlo leslons compared wllh Iho placebo gmups. In the 
placebo groups, the percent diameter slenosls at follow up period of resteno. 
ala leslon wss slgnlfloantly larger lhsn that of de novo lesion (’ p = O.O2S), also 
lho bolh were slmllsr In tranllasl groups. The results Imply that trsnllss\ was 
more offecllve for preventlon of restenosls followlng re.PTCA agalnst resle. 
nosls. Tho mechanism may depend on the psthologlcal basis of the lesion. 
Tranllart Inhlblta Noolntlms Formation In 
Balloon-Injured and Stonted Pig Coronary 
ARorle8, end Decrea1108 Negative Romodollng 
After Balloon ln]ury 
S. lahlwotn, N.A.P. Chronos, Q. lln, J-J. Mmshsll, S.B. King, 111, 
K,A. Roblnson. De~rfman~ of tWerIc/nQ (CrQrWagy~, Emory Univ?mifY 
School al Madk~m. Atlanta, &IA: VA MedIcal Cenrer, Allonta, (iA, USA 
Fow phannnoologla nganla aftact restanosm cllnically. A recent huge mum= 
cenlar trml (TREAT) shawad benekt (15% restsnosm rata) at the anli-allew 
nnd nnli.kolold oompaund To conlw thus result and ascerlsin the posse. 
bla machnnism wa gsva 100 mgncg hanilast twme/d for 3 d More balloon 
anglaplnsty In the LAD and LCX, and stenhng in the RCA tn 18 pugs and 
conlinuad until hssua hntvosl al 28 d. Contrals (n ‘i la) received angiaplesty 
and slam only. Camnary specimans (stems processed tn situ) were analyzed 
by somaulenrod hlstomorphomaby. 
Resulfs: Trnnilast stgntltaantly drcmasad noatnbmn SIZO (IA) normakrod 
to the orlen~ 01 rnlury (FL) nnd increased lumen size (LA) relskve to ovemtl 
voaasl alxa (VA) in ballwn4nhmrd vassals; advenhha siao (AA) as an index 
of rfrmOdQllng. was decreased. 
lklllooncd WSJ& IPJFL LANA AA 
control 074 ,019 04R i 0.w 052 t 021 
mulnnl 047 t 009 o!at 009 043t014 
1’ va1ua Sludonll 00001 0 0038 00037 
Trnnilnsl nlso tnhibttod neotntlma lormalton whether axpressed as abso- 
Iulo area (slallstical trend) or relalive lo the extent of m(ury (IS). tn stented 
vassels 
IA l&IS 
407 f 042 TaBt 027 
trmlasl 3.26 t 04 204t025 
p valuoSludonll 0136 0022 
Conclususcons: Trantlast IS elfeclive lo mhtbtl neomltma IonnatIon and ad- 
venbtial remodetlng m the ptg coronary model of ballwn reslenosts. and 
mhtbils nootnttma tn slants: 11 may be usolul ckntcelly. Studtes lo further 
dokno tho mechanism aro underway. 
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immediate release angtopeplin has prevtousty been shown to decrease clm- 
tcal events followtng PTCA. The purpose of the present study was to assess 
the eflicacy of angtopepbn prolonged release (PR) on the combtned pnmaty 
endpomls 01 deatn. Ml and revasculanzahon tcitowmg PTCA al one year. 
Methods: 274 patients were enrolled al 7 centers m thts randomized 
double-bknd placebo-controlled study. Study drug (30 mg angiopepbn PR or 
placebo) was given as a single mlramuscular injection the day before the 
scheduled PTCA. As in Ihe prevtous study, a booster dose of 375 rig was 
given 15 minutes prior lo inflation. All procedural angiograms were evaluated 
at the core laboratory. Clinical fallow-up was performed at 6 and 12 months. 
Pnmary endpoints were analyzed in a hierarchical manner. 
Resurrs: Follow-up was completed July 3rd 1997. There were 206 males 
(75%) and 66 females (25%). mean age 61 and 57 year, respectively. The 
incidence of diabetes was 9%. Overall. the drug was well tolerated. At interim 
angiographic analysis. study lesions were located in LAD tn 55%, LCX in 19% 
and RCA in 26%. Lesion lenglh exceeded 10 mm in 37% of the cases. Mean 
reference diameter was 2.9 mm. The overall clinical event rate was 26.796 m 
the successful PTCA population at one year. 
Conclusion: In this study, angiopeptin PR was well tolerated. Final eliicacy 
results wtll be available by October 1997. 
